Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
Reads0
Chats0
TLDR
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.About:
This article is published in The Lancet.The article was published on 2010-10-02. It has received 1758 citations till now. The article focuses on the topics: Fludarabine & FCR Regimen.read more
Citations
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
TL;DR: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Journal ArticleDOI
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Journal ArticleDOI
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Journal ArticleDOI
Mutations driving CLL and their evolution in progression and relapse.
Dan A. Landau,Eugen Tausch,Amaro Taylor-Weiner,Chip Stewart,Johannes G. Reiter,Jasmin Bahlo,Sandra Kluth,Ivana Bozic,Michael S. Lawrence,Sebastian Böttcher,Scott L. Carter,Scott L. Carter,Kristian Cibulskis,Daniel Mertens,Daniel Mertens,Carrie Sougnez,Mara Rosenberg,Julian M. Hess,Jennifer Edelmann,Sabrina Kless,Michael Kneba,Matthias Ritgen,A. M. Fink,Kirsten Fischer,Stacey Gabriel,Eric S. Lander,Martin A. Nowak,Hartmut Döhner,Michael Hallek,Michael Hallek,Donna Neuberg,Gad Getz,Gad Getz,Stephan Stilgenbauer,Catherine J. Wu +34 more
TL;DR: Large sequencing data sets of clinically informative samples enable the discovery of novel genes associated with cancer, the network of relationships between the driver events, and their impact on disease relapse and clinical outcome.
References
More filters
Journal ArticleDOI
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner,Stephan Stilgenbauer,Axel Benner,Elke Leupolt,Alexander Kröber,Lars Bullinger,Konstanze Döhner,Martin Bentz,Peter Lichter +8 more
TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps +10 more
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Journal ArticleDOI
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Terry J. Hamblin,Zadie Davis,Zadie Davis,Anne Gardiner,Anne Gardiner,David G. Oscier,David G. Oscier,Freda K. Stevenson,Freda K. Stevenson +8 more
TL;DR: In this paper, the authors sequenced the Ig V(H) genes of the tumor cells of 84 patients with CLL and correlated their findings with clinical features, finding that the lack of somatic mutation and trisomy 12 was associated with a less favorable prognosis.
Journal ArticleDOI
Clinical staging of chronic lymphocytic leukemia.
Kanti R. Rai,Arthur Sawitsky,Eugene P. Cronkite,Arjun D. Chanana,Robert N. Levy,Bernard S. Pasternack +5 more
TL;DR: The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients and sex and age were shown to be poor predictors of survival after adjustment for stage.
Journal ArticleDOI
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
Related Papers (5)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more